Respected Sir/Ma'am, With reference to the notice issued on February 03, 2026, we would like to inform you that the Board of Directors of the Company at their meeting held on February ....
Awaiting price reaction for this filing.
The Board approved unaudited standalone financial results for Q3 and nine months ended December 31, 2025. Revenue from operations surged to ₹3,777.74 lakhs in Q3 FY26 from nil in Q3 FY25, while nine-month revenue jumped to ₹7,826.14 lakhs versus just ₹2.05 lakhs a year earlier, reflecting a sharp ramp-up in business activity. Profit after tax rose to ₹314.12 lakhs in Q3 (vs ₹32.04 lakhs) and ₹722.29 lakhs for 9M FY26 (vs ₹86.53 lakhs), with EPS of ₹12.12 for the quarter and ₹27.87 for nine months. The company also disclosed four fund raises via preferential allotment of convertible warrants in December 2025 totalling roughly ₹2,339 lakhs, intended for repaying SBI borrowings, setting up an oncology (Lipid Complex Injections) unit, and general corporate purposes, with no deviation in utilisation. Statutory auditor Patel Jain & Associates has been renamed to Bhatt Shah Mekhia & Co, though the firm entity itself remains unchanged.
Strong revenue and profit growth signals a significant business turnaround, likely to be viewed positively by investors. However, the bulk of growth hinges on a newly operational business line, so sustainability will be the key thing to watch. The fresh capital supports debt reduction and a new oncology manufacturing venture, which could drive future earnings.